7 results match your criteria: "Hospital Universitario Puerta del Mar (HUPM)[Affiliation]"
Med Clin (Barc)
March 2024
Servicio de Oncología Médica, Hospital Universitario Puerta del Mar (HUPM), Cádiz, España; Instituto de Investigación e Innovación Biomédica de Cádiz (INIBiCA), Cádiz, España. Electronic address:
Background And Objective: Reproductive history influences breast cancer risk. We analysed its association with tumour subtype and survival in premenopausal women.
Patients And Methods: Retrospective, observational study of premenopausal women with stage I-III breast carcinoma in the last 20 years.
Healthcare (Basel)
August 2023
Department of Statistics and Operations Research, Faculty of Medicine, University of Cadiz, 11002 Cádiz, Spain.
Polypharmacy has been linked to cognitive decline. However, interventions targeting modifiable risk factors, some of which are targets of the most commonly used drugs, could reduce the prevalence of dementia. Our aim was to determine the drug prescription regimen at baseline, prior to the diagnosis of mild cognitive impairment (MCI), and its possible association with progression to dementia.
View Article and Find Full Text PDFSci Rep
May 2023
Medical Oncology Department, Hospital Universitario Puerta del Mar (HUPM), Ana de Viya 21, 11009, Cádiz, Spain.
Adjuvant trastuzumab in HER2+ breast cancer reduces recurrence and mortality, and has been the standard treatment since 2006. The objective was to analyze health outcomes in the real world. Observational, retrospective study of patients with HER2+ breast cancer, stages I-III, treated with adjuvant trastuzumab in the past 15 years in only one center and for the first time in Spain.
View Article and Find Full Text PDFSci Rep
June 2021
Department of Biochemistry, Faculty of Medicine, University of Cadiz, Plaza Fragela, s/n, 11003, Cadiz, Spain.
Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and influence of the patients' baseline characteristics. Data from 250 MS outpatients were collected during the period 1981-2019 from the medical records of the Neurology Service of the HUPM (Hospital Universitario Puerta del Mar)-in Southern Spain-and analysed using Cox models.
View Article and Find Full Text PDFEur J Immunol
July 2019
Servicio de Inmunología, UGC de Hematología, Inmunología y Genética, Hospital Universitario Puerta del Mar (HUPM), Cádiz, Spain.
Systemic lupus erythematosus and rheumatoid arthritis are autoimmune diseases characterised by B-cell hyperactivation and production of autoantibodies (AutoAbs) against various self-antigens, including extractable nuclear antigens and citrullinated peptides. Therefore, B lymphocytes and antibody-secreting cells are considered relevant targets for therapies. However, isolation and characterisation of auto-reactive specific B lymphocytes are limited, primarily due to technical issues.
View Article and Find Full Text PDFJ Pediatr Hematol Oncol
November 2017
*Department of Immunology, Hematology and Immunology Unit. Hospital Universitario Puerta del Mar (HUPM) †Department of Hematology, Hematology and Immunology Unit. HUPM ‡Pediatric Intensive Care Department, Pediatrics Unit. HUPM. Cádiz, Spain.
Hemophagocytic lymphohistiocytosis is characterized by uncontrolled activation of the immune system that leads to systemic hyperinflammation. Lymphoproliferative syndrome linked to the X chromosome is a hereditary immunodeficiency characterized by an inability to mount an adequate immune response to an Epstein-Barr virus infection. Hemophagocytic lymphohistiocytosis is one of the main clinical features of X-linked lymphoproliferative syndrome.
View Article and Find Full Text PDFEur J Immunol
July 2017
Servicio de Inmunología, UGC de Hematología e Inmunología, HUPM, Cádiz.
Disturbances of plasma cell homeostasis and auto-antibody production are hallmarks of systemic lupus erythematosus. The aim of this study was to explore the presence of circulating anti-ENA and anti-dsDNA antibody-secreting cells, to determine their dependence on plasma cell-niche cytokines and to analyze their clinical value. The study was performed in SLE patients with serum anti-ENA and/or anti-dsDNA antibodies (n = 57).
View Article and Find Full Text PDF